000 02358cam a2200349 a 4500
003 EG-GiCUC
005 20250223032539.0
008 200809s2020 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.03.Ph.D.2020.As.C
100 0 _aAsmaa Mohamed Atef Abdelrahman
245 1 0 _aCytokine receptor like factor 2 (CRLF2)- overexpressing pediatric Precursor B- acute lymphoblastic leukemia :
_bAn approach towards individualized therapy /
_cAsmaa Mohamed Atef Abdelrahman ; Supervised Nayera Hamdy Elshakankiry , Emad Nabil Ebeid , Eman Omar Rasekh
246 1 5 _aزيادة تعبير العامل المماثل للمستقبلات الخلوية-2 فى الأطفال المصابين بسرطان الدم الأولى ب الليمفاوى الحاد :
_bنهج نحو العلاج الفردى
260 _aCairo :
_bAsmaa Mohamed Atef Abdelrahman ,
_c2020
300 _a153 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
520 _aIntroduction: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a neoplastic proliferation of lymphoblasts that has a gene expression profile similar to that of BCR-ABL1 positive B-ALL, but lacks the disease-defining Philadelphia chromosome. Growing evidence has proved that alterations in the cytokine receptor-like factor 2 gene (CRLF2)that result in CRLF2 overexpression associates with poor treatment outcomes thus highlighting a potentially important oncogenic mechanism in a subset of patients. The significant association of CRLF2 overexpression with JAK2 mutation suggests that these patients may benefit from future kinase inhibitor approaches. In addition, cell surface-expressed CRLF2 itself may be a potential target for anti-CRLF2 antibody based therapies
530 _aIssued also as CD
653 4 _aB cell precursor ALL
653 4 _aCRLF2
653 4 _aPhiladelphia-like ALL
700 0 _aEmad Nabil Ebeid ,
_eSupervisor
700 0 _aEman Omar Rasekh ,
_eSupervisor
700 0 _aNayera Hamdy Elshakankiry ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c77123
_d77123